Innovative Approach and Promising Data Drive Buy Rating for Aura Biosciences
Evercore ISI analyst Jonathan Miller maintains a Buy rating for Aura Biosciences due to its innovative approach and promising early data. Aura's unique mechanism targets tumor cells in early-stage indications, offering new treatment options for conditions like bladder cancer and uveal melanoma. Despite competition, Aura's progress in uveal melanoma presents a compelling investment opportunity. H.C. Wainwright also reiterates a Buy rating with a $22 price target.
Evercore ISI analyst Jonathan Miller has maintained their bullish stance on AURA stock, giving a Buy rating on November 14.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Jonathan Miller has given his Buy rating due to a combination of factors including Aura Biosciences Inc’s innovative approach and promising early data. The company employs a unique mechanism of action using a photosensitive payload to target tumor cells in early-stage indications, which are currently underserved. This approach could potentially open up new treatment options for conditions like neoadjuvant non-muscle invasive bladder cancer and very early uveal melanoma, where traditional treatments are not typically considered.
Furthermore, Aura Biosciences is making significant progress with its registrational program in uveal melanoma, known as CoMpass. Despite the competitive landscape, particularly in non-muscle invasive bladder cancer, Aura’s advancements and upcoming catalysts in uveal melanoma present a compelling investment opportunity. These factors, coupled with a revamped model, contribute to Miller’s positive outlook and Buy rating for the stock.
According to TipRanks, Miller is an analyst with an average return of -5.0% and a 41.38% success rate. Miller covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Intellia Therapeutics, and Dynavax.
In another report released on November 14, H.C. Wainwright also reiterated a Buy rating on the stock with a $22.00 price target.
